BPIQ Blog

FDA Decision on Heron's Non-Opioid Pain Med Imminent

We think Heron (HRTX) has a very good chance of approval by the FDA by the April 30, 2019 due date for its non-opioid pain med HTX-011....

Apr 29, 20195 min read

BIopharma companies (Concert and Incyte) patent dispute.

Apr 8, 201910 min read

(For a longer version of this article, with more detailed legal facts, please CLICK HERE.) Concert (CNCE) and Incyte (INCY) have been...

Apr 8, 20197 min read

Sangamo (SGMO) provided an update today on its clinical programs, with its first clinical data for its Phase I Hemophilia A (gene...

Apr 2, 20192 min read

Yesterday, Heron (HRTX) reported additional data for its opioid-free pain med candidate HTX-011 in a post-surgery setting. In the latest...

Mar 12, 20191 min read

Our platform helps you uncover your next biotech investment opportunity